Montelukast improves disease outcome in SOD1 G93A female mice by counteracting oligodendrocyte dysfunction and aberrant glial reactivity
British Journal of Pharmacology · 2024
DOI: 10.1111/bph.16408 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Pharmacology, 2024. Verfasst von Stefano Raffaele und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular and Cellular Pharmacology of Purinergic Transmission, Department of Pharmacological and Biomolecular Sciences "Rodolfo Paolet…. Hauptthemen laut MEDLINE: Cyclopropanes, Quinolines, Acetates, Oligodendroglia. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AriSLA ETS - Fondazione Italiana di ricerca per la SLA, Italian Ministry of University and Research (MUR), #NEXTGENERATIONEU (NGEU) and the Italian Ministry of University and Research (MUR), NRRP - National Recovery and Resilience Plan.
Abstract (Originalsprache)
Background and Purpose Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by progressive motor neuron (MN) loss and consequent muscle atrophy, for which no effective therapies are available. Recent findings reveal that disease progression is fuelled by early aberrant neuroinflammation and the loss of oligodendrocytes with neuroprotective and remyelinating properties. On this basis, pharmacological interventions capable of restoring a pro‐regenerative local milieu and re‐establish proper oligodendrocyte functions may be beneficial. Experimental Approach Here, we evaluated the in vivo therapeutic effects of montelukast (MTK), an antagonist of the oligodendroglial G protein‐coupled receptor 17 (GPR17) and of cysteinyl‐leukotriene receptor 1 (CysLT 1 R) receptors on microglia and astrocytes, in the SOD1 G93A ALS mouse model. We chronically treated SOD1 G93A mice with MTK, starting from the early symptomatic disease stage. Disease progression was assessed by behavioural and immunohistochemical approaches. Key Results Oral MTK treatment significantly extended survival probability, delayed body weight loss and ameliorated motor functionalityonly in female SOD1 G93A mice. Noteworthy, MTK significantly restored oligodendrocyte maturation and induced significant changes in the reactive phenotype and morphological features of microglia/macrophages and astrocytes in the spinal cord of female SOD1 G93A mice, suggesting enhanced pro‐regenerative functions. Importantly, concomitant MN preservation has been detected after MTK administration. No beneficial effects were observed in male mice, highlighting a sex‐based difference in the protective activity of MTK. Conclusions and Implications Our results provide the first preclinical evidence indicating that repurposing of MTK, a safe and marketed anti‐asthmatic drug, may be a promising sex‐specific strategy for personalized ALS treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Molecular and Cellular Pharmacology of Purinergic Transmission, Department of Pharmacological and Biomolecular Sciences "Rodolfo Paoletti", Università degli Studi di Milano, Milan, Italy.
- Department of Pharmacy, Unit of Pharmacology and Toxicology, Università degli Studi di Genova, Genoa, Italy.
- IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
- Laboratory of Molecular and Cellular Pharmacology of Purinergic Transmission, Department of Pharmaceutical Sciences, Università degli Studi di Milano, Milan, Italy.
- Inter-University Center for the Promotion of the 3R Principles in Teaching and Research (Centro 3R), Pisa, Italy.
ORCID-Profile: Stefano Raffaele, Marta Fumagalli
Förderung
- AriSLA ETS - Fondazione Italiana di ricerca per la SLA
- Italian Ministry of University and Research (MUR)
- #NEXTGENERATIONEU (NGEU) and the Italian Ministry of University and Research (MUR), NRRP - National Recovery and Resilience Plan
- Foundation Bellandi Bernardoni
- Agenzia di Ricerca per la Sclerosi Laterale Amiotrofica
- Ministero dell'Università e della Ricerca
Zitieren
APA
Raffaele, S., Nguyen, N., Milanese, M., Mannella, F. C., Boccazzi, M., Frumento, G., Bonanno, G., Abbracchio, M. P., Bonifacino, T., & Fumagalli, M. (2024). Montelukast improves disease outcome in SOD1 G93A female mice by counteracting oligodendrocyte dysfunction and aberrant glial reactivity. British Journal of Pharmacology. https://doi.org/10.1111/bph.16408
Vancouver
Raffaele S, Nguyen N, Milanese M, Mannella FC, Boccazzi M, Frumento G, et al. Montelukast improves disease outcome in SOD1 G93A female mice by counteracting oligodendrocyte dysfunction and aberrant glial reactivity. British Journal of Pharmacology. 2024. doi:10.1111/bph.16408
BibTeX
@article{Raffaele2024,
author = {Raffaele, Stefano and Nguyen, Nhung and Milanese, Marco and Mannella, Francesca C and Boccazzi, Marta and Frumento, Giulia and Bonanno, Giambattista and Abbracchio, Maria P and Bonifacino, Tiziana and Fumagalli, Marta},
title = {Montelukast improves disease outcome in SOD1 G93A female mice by counteracting oligodendrocyte dysfunction and aberrant glial reactivity},
journal = {British Journal of Pharmacology},
year = {2024},
doi = {10.1111/bph.16408}
}
EUVIMED